Nasdaq
$60.59▲ 0.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.03BShares out 83.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
28- 10.16After-hours26.10.17 06:204Ownership#●●●
PTC THERAPEUTICS, INC.
Insider Michael Schmertzler of PTC THERAPEUTICS, INC. filed a Form 4 report regarding changes in his beneficial ownership of securities as of October 14, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$60.59+0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13After-hours26.10.14 06:204Ownership
PTC THERAPEUTICS, INC.
PTC Therapeutics insider Mark Elliott Boulding filed a Form 4 report on October 9, 2026, regarding changes in beneficial ownership of securities. This filing serves as a standard disclosure of insider equity transactions.…more
$60.59+0.03%vs prev closeView filingShare - 10.9After-hours26.10.10 06:204Ownership
PTC THERAPEUTICS, INC.
Director Michael Schmertzler of PTC Therapeutics filed a statement of changes in beneficial ownership of securities on October 7, 2026. This filing serves as a routine disclosure regarding the director's equity holdings.…more
$60.59+0.03%vs prev closeView filingShare
27 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.24Pre-market26.08.24 21:07#●●●#●●●
PTC Therapeutics to Present New Sephience Clinical Data at SSIEM 2026
PTC Therapeutics will present new clinical and real-world data for its PKU treatment, Sephience, highlighting its efficacy in lowering phenylalanine levels and improving patient quality of life. While the data reinforces the drug's clinical benefits and safety profile, it does not represent a new regulatory approval or immediate financial impact.…more
$60.59+0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga